Fortify Ventures Announces Distilled Intelligence 3.0 Investor Summit and National Pitch Competition for Seed to Series A Startups
WASHINGTON--(BUSINESS WIRE)-- Fortify Ventures, in collaboration with Loudoun County's Department of Economic Development, proudly announces Distilled Intelligence 3.0 (DI 3.0), set to take place from October 13-16, 2025, at the Lansdowne Resort in Leesburg, Virginia. This invitation-only investor summit and national pitch event will bring together some of the nation's brightest startup founders, top-tier investors, influential family offices, and seasoned operators to catalyze impactful relationships and drive investment momentum.
To ensure the summit remains accessible, selected founders will receive complimentary hotel accommodations and meals throughout the event, needing only to arrange their travel to Leesburg, Virginia.
Share
Distilled Intelligence has a notable history of identifying and showcasing early-stage companies that later achieved unicorn status, including Hinge and ID.me. With DI 3.0, Fortify Ventures continues this legacy by evolving the event beyond a traditional pitch competition into a comprehensive, four-day immersive experience designed to foster meaningful connections, high-value deal flow, and strategic partnerships.
The event will feature approximately 100 carefully selected seed to series A startups representing cutting-edge innovation across a wide variety of sectors, including human health, cybersecurity, defense tech, energy, and future-of-work.
Participating startups will have the chance to compete for a substantial prize of $1 million in the form of SAFE note, providing critical funding to help accelerate their growth and development. However, the pitching component is just one facet of this dynamic summit. Beyond the pitches, DI 3.0 emphasizes in-depth interactions and robust relationship-building opportunities designed to connect startups directly with the investors and partners most relevant to their specific needs.
The agenda for DI 3.0 is thoughtfully curated to maximize both structured and unstructured networking opportunities. The event begins with an opening VIP dinner on Monday, October 13, and continues with industry-specific breakout sessions, keynote speeches, and panel discussions featuring industry-leading experts. Attendees can also engage in a variety of recreational activities, such as golf, tennis, pickleball, yoga, a run club, and informal gatherings like evening campfire discussions. This intentional balance of structured sessions and relaxed networking settings creates an environment that encourages authentic conversations and long-term relationships.
Participants will find that DI 3.0 goes beyond typical industry conferences by providing a comfortable, engaging atmosphere and a curated off-site experience for founders, investors, and operators. Attendees are encouraged to connect organically, whether in a roundtable session or on the tennis court, fostering deep discussions and genuine interactions that extend well beyond the event itself. This unique approach is designed to create an impactful experience, leaving attendees inspired, recharged, and well-connected.
Founders interested in participating in DI 3.0 can submit applications directly through the event's official website at DistilledIntelligence.com. Fortify Ventures, alongside their co-investment partners, will carefully assess startups based on the strength of the team, market potential, product innovation, and demonstrated traction. To ensure the summit remains accessible, selected founders will receive complimentary hotel accommodations and meals throughout the event, needing only to arrange their travel to Leesburg, Virginia.
At DI 3.0, investors will receive exclusive access to carefully selected, high-conviction investment opportunities, including emerging venture funds and targeted co-investments with premier firms. Participating venture funds will engage in substantive dialogue, exchange valuable insights, and explore strategic collaborations designed to foster genuine relationships and meaningful alignment, emphasizing trust and depth over transactional networking.
In a new initiative, DI 3.0 also welcomes experienced startup operators. These invited guests bring valuable operational insights and practical experience that can significantly benefit both investors and early-stage startups at the event. Operators attending the summit also present opportunities for future collaboration, mentorship, and potentially new ventures.
Fortify Ventures and Loudoun County's Department of Economic Development have crafted DI 3.0 to provide comprehensive amenities and hospitality, ensuring that attendees can fully immerse themselves in the event without distractions. Accommodations, meals, and activities are thoughtfully included, providing a seamless experience that focuses solely on facilitating meaningful interactions.
'Distilled Intelligence 3.0 is more than just another investor event—it's a meticulously curated gathering designed to nurture the next generation of transformative businesses,' said Jonathon Perrelli, Managing Partner at Fortify Ventures. 'We're committed to bringing together brilliant minds, actionable opportunities, and fostering an environment where innovation thrives.'
'Loudoun County is honored to co-host DI 3.0, an event perfectly aligned with our mission of driving innovation and economic growth,' said Buddy Rizer, Executive Director of Loudoun Economic Development. 'Our region continues to attract dynamic entrepreneurs and influential investors, and DI 3.0 exemplifies the spirit of innovation and strategic growth Loudoun County stands for.'
The event schedule, list of speakers, and the selected founders will be announced at a later date.
Founders of seed and series A startups may apply now through September 15, 2025, at https://www.distilledintelligence.com/. Selections will be made on a rolling basis, and companies are encouraged to apply early for an increased opportunity to be selected. Venture funds, angel investors, family offices, and strategic partners interested in attending or sponsoring can request invitations by emailing hello@fortify.vc.
For media inquiries and complimentary registration, please contact: kari@redironpr.com
About Fortify Ventures
Founded in 2011, Fortify Ventures is a venture capital ecosystem that invests in early-stage founders disrupting the status quo. The firm invests in people building innovative and disruptive technologies for human health, the future of work, and the infrastructure that powers both. Fortify provides its portfolio companies with robust community and operational guidance to maximize their impact. The company's reach extends far beyond capital, providing portfolio companies with operators, thinkers, executors, and change makers all aligned on a mission to move one step closer to tomorrow's world. The company's rich history includes more than 35 investments to date, nearly 10 successful exits, including Hinge, ID.me, and Socialtables. The company is headquartered in the Washington, DC area.
About Loudoun Economic Development
Loudoun County, Virginia, is one of the nation's fastest-growing and most innovative business hubs. Loudoun Economic Development empowers companies of all sizes to start, scale, and soar by delivering concierge-level service, fostering a vibrant ecosystem of entrepreneurship and investment, and promoting sustainable, diversified growth. From global tech leaders to visionary startups, businesses choose Loudoun for its unmatched connectivity, top-tier talent, and business-friendly environment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Business Wire
a day ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
a day ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
